Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes.
Hepatitis C
genetics
genome to genome analysis
genomics
human
infectious disease
integration analysis
interferon lambda polymorphism
microbiology
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
03 09 2019
03 09 2019
Historique:
received:
03
10
2018
accepted:
31
05
2019
entrez:
4
9
2019
pubmed:
4
9
2019
medline:
20
2
2020
Statut:
epublish
Résumé
Genetic polymorphism in the interferon lambda (IFN-λ) region is associated with spontaneous clearance of hepatitis C virus (HCV) infection and response to interferon-based treatment. Here, we evaluate associations between IFN-λ polymorphism and HCV variation in 8729 patients (Europeans 77%, Asians 13%, Africans 8%) infected with various viral genotypes, predominantly 1a (41%), 1b (22%) and 3a (21%). We searched for associations between rs12979860 genotype and variants in the NS3, NS4A, NS5A and NS5B HCV proteins. We report multiple associations in all tested proteins, including in the interferon-sensitivity determining region of NS5A. We also assessed the combined impact of human and HCV variation on pretreatment viral load and report amino acids associated with both IFN-λ polymorphism and HCV load across multiple viral genotypes. By demonstrating that IFN-λ variation leaves a large footprint on the viral proteome, we provide evidence of pervasive viral adaptation to innate immune pressure during chronic HCV infection.
Identifiants
pubmed: 31478832
doi: 10.7554/eLife.42542
pii: 42542
pmc: PMC6721370
doi:
pii:
Substances chimiques
Immunologic Factors
0
Viral Nonstructural Proteins
0
interferon-lambda, human
0
Interferons
9008-11-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swiss National Science Foundation
ID : PP00P3_157529
Pays : Switzerland
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019, Chaturvedi et al.
Déclaration de conflit d'intérêts
NC, JF No competing interests declared, ES, HM, AO, DB, GS, JM This study was partially funded by Gilead Sciences and the author is an employee of Gilead Sciences, SZ has been a consultant for Abbvie, Gilead, Janssen, Merck/MSD
Références
Elife. 2019 Sep 03;8:
pubmed: 31478832
J Gen Virol. 2004 Nov;85(Pt 11):3173-3188
pubmed: 15483230
World J Gastroenterol. 2014 Mar 21;20(11):2902-12
pubmed: 24659881
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Hepatology. 2014 Jan;59(1):318-27
pubmed: 24115039
J Clin Invest. 1995 Jul;96(1):224-30
pubmed: 7542279
PLoS One. 2014 Mar 05;9(3):e90581
pubmed: 24599324
Nat Genet. 2013 Feb;45(2):164-71
pubmed: 23291588
Bioinformatics. 2014 Mar 1;30(5):614-20
pubmed: 24142950
Hepatology. 1998 Dec;28(6):1674-9
pubmed: 9828234
Nat Genet. 2009 Oct;41(10):1105-9
pubmed: 19749757
J Hepatol. 2017 Aug;67(2):224-236
pubmed: 28343981
Hepatology. 2016 Jan;63(1):63-73
pubmed: 26406534
Adv Virus Res. 2004;63:71-180
pubmed: 15530561
Nat Genet. 2017 May;49(5):666-673
pubmed: 28394351
Nature. 2009 Sep 17;461(7262):399-401
pubmed: 19684573
Evolution. 2009 Dec;63(12):3258-68
pubmed: 19663993
Elife. 2013 Oct 29;2:e01123
pubmed: 24171102
BMC Genomics. 2012 Sep 13;13:475
pubmed: 22974120
Nature. 2009 Oct 8;461(7265):798-801
pubmed: 19759533
Front Microbiol. 2014 Jul 03;5:329
pubmed: 25071742
Gastroenterology. 2010 Apr;138(4):1338-45, 1345.e1-7
pubmed: 20060832
Hepatology. 2011 Feb;53(2):396-405
pubmed: 21246583
Lancet Infect Dis. 2005 Sep;5(9):558-67
pubmed: 16122679
Semin Liver Dis. 2000;20(1):17-35
pubmed: 10895429
Science. 2000 Apr 14;288(5464):339-44
pubmed: 10764648
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147